沃特世 WAT 深 滬
已收盤 02-06 16:00:00 美东时间
381.29
+4.400
+1.17%
華盛通- 最 高383.885
- 今 開377.18
- 成交量 78.53万股
- 最 低 369.40
- 昨 收 376.89
- 總市值 227.05亿
- 52周最高 414.15
- 市盈率 靜 35.60
- 換手率 1.32%
- 52周最低 275.05
- 委 比 -33.33%
- 總股本 5954.77万
- 歷史最高 428.22
- 量 比 1.06
- 振 幅 3.84%
- 歷史最低 70.88
- 每 手 1
- 風險率 36.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
6 Analysts Have This To Say About Waters
In the preceding three months, 6 analysts have released ratings for Waters (NYS...
01-28 04:01
HSBC Initiates Coverage On Waters with Buy Rating, Announces Price Target of $460
HSBC analyst Sidharth Sahoo initiates coverage on Waters (NYSE:WAT) with a Buy rating and announces Price Target of $460.
01-27 21:44
Waters-Becton Dickinson Deal May Deliver Bigger Gains Than Expected: Analyst
William Blair starts coverage on Waters with an Outperform rating, saying the BD merger could drive strong earnings growth and about 20% upside as investor confidence improves.
01-07 02:48
Federal appeals court rejects NIH research funding cuts
A U.S. appeals court has ruled against the Trump administration’s moves to implement drastic cuts to federal grant funding provided by the National Institutes of Health (NIH) to cover overhead costs i...
01-06 20:16
William Blair Initiates Coverage On Waters with Outperform Rating
William Blair analyst Matt Larew initiates coverage on Waters (NYSE:WAT) with a Outperform rating.
01-05 21:50
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
Wolfe Research Upgrades Waters to Outperform, Announces $48 Price Target
Wolfe Research analyst Doug Schenkel upgrades Waters (NYSE:WAT) from Peer Perform to Outperform and announces $48 price target.
2025-12-11 00:28
